Low preoperative cholesterol level is a risk factor of sepsis and poor clinical outcome in patients undergoing cardiac surgery with cardiopulmonary bypass

Critical Care Medicine

Volumn 42, Issue 5, 2014, Pages 1065-1073

  Lagrost, Laurent ^a,b,d   Girard, Claude ^a,b,e   Grosjean, Sandrine ^a,b   Masson, David ^a,b   Deckert, Valérie ^a   Gautier, Thomas ^a   Debomy, Frédérique ^b   Vinault, Sandrine ^c   Jeannin, Aline ^a   Labbé, Jérôme ^a   Bonithon Kopp, Claire ^a,c  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^e HÔPITAL DU BOCAGE   (France)

Author keywords

cardiopulmonary bypass; cholesterol; inflammation; sepsis

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; INTERLEUKIN 8; PROCALCITONIN;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CHOLESTEROL BLOOD LEVEL; CORRELATION ANALYSIS; FEMALE; HEART SURGERY; HEMODILUTION; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE UNIT; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CALCITONIN; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CHOLESTEROL; CYTOKINES; FEMALE; HUMANS; INTENSIVE CARE; LIPOPROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; SEPSIS; SURGICAL PROCEDURES, ELECTIVE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 84899586503     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000165     Document Type: Article

References (33)

1. Day JR, Taylor KM: The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 2005; 3:129-140
2. Martinez-Pellús AE, Merino P, Bru M, et al: Can selective digestive decontamination avoid the endotoxemia and cytokine activation promoted by cardiopulmonary bypass? Crit Care Med 1993; 21:1684-1691
3. Jansen NJ, van Oeveren W, Gu YJ, et al: Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54:744-747; discussion 747-748
4. Shann KG, Likosky DS, Murkin JM, et al: An evidence-based review of the practice of cardiopulmonary bypass in adults: A focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg 2006; 132:283-290
5. Rocke DA, Gaffin SL, Wells MT, et al: Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93:832-837
6. Klein DJ, Briet F, Nisenbaum R, et al: Endotoxemia related to cardiopulmonary bypass is associated with increased risk of infection after cardiac surgery: A prospective observational study. Crit Care 2011; 15:R69
7. Netea MG, Demacker PN, Kullberg BJ, et al: Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest 1996; 97: 1366-1372
8. Chien JY, Jerng JS, Yu CJ, et al: Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005; 33:1688-1693
9. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930-933
10. Kalantar-Zadeh K, Block G, Horwich T, et al: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43:1439-1444
11. Gordon BR, Parker TS, Levine DM, et al: Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 2001; 29:1563-1568
12. Rocke DA, Gaffin SL, Wells MT, et al: Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1987; 93:832-837
13. Roques F, Nashef SA, Michel P, et al: Risk factors and outcome in European cardiac surgery: Analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15:816-822; discussion 822-823
14. Rothenburger M, Soeparwata R, Deng MC, et al: The impact of anti-endotoxin core antibodies on endotoxin and cytokine release and ventilation time after cardiac surgery. J Am Coll Cardiol 2001; 38:124-130
15. Mishra J, Dent C, Tarabishi R, et al: Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365:1231-1238
16. Di Stefano S, Casquero E, Bustamante R, et al: Analysis of inflammatory response and utility of N-terminal pro brain-type natriuretic peptide in cardiac surgery with extracorporeal circulation. J Cardiovasc Med (Hagerstown) 2008; 9:555-560
17. Samy K, Anouar J, Mnif E, et al: N-terminal pro-brain natriuretic peptide identifies patients at risk for occurrence of postoperative atrial fibrillation in cardiac surgery with cardiopulmonary bypass. Ann Card Anaesth 2012; 15:199-205
18. Harbarth S, Holeckova K, Froidevaux C, et al; Geneva Sepsis Network: Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164:396-402
19. Uzzan B, Cohen R, Nicolas P, et al: Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003
20. Hall TS: The pathophysiology of cardiopulmonary bypass. The risks and benefits of hemodilution. Chest 1995; 107:1125-1133
21. Iribarren C, Jacobs DR Jr, Sidney S, et al: Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 1998; 121:335-347
22. Almog Y, Shefer A, Novack V, et al: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004; 110:880-885
23. Coleman CI, Lucek DM, Hammond J, et al: Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin 2007; 23:1783-1790
24. Ray KK, Cannon CP: The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46:1425-1433
25. Florens E, Salvi S, Peynet J, et al: Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study. J Card Surg 2001; 16:232-239
26. Fraunberger P, Gröne E, Gröne HJ, et al: Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. Shock 2009; 32:159-163
27. Franke A, Lante W, Fackeldey V, et al: Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: Is what we see what we know? Eur J Cardiothorac Surg 2005; 28:569-575
28. Weiland AP, Walker WE: Physiologic principles and clinical sequelae of cardiopulmonary bypass. Heart Lung 1986; 15:34-39
29. Hill GE, Pohorecki R, Whitten CW: Plasma lipid concentrations correlate inversely with CPB-induced interleukin-6 release. Can J Anaesth 1998; 45:509-514
30. Carmona F, Manso PH, Vicente WV, et al: Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: A multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I. Cytokine 2008; 42:317-324
31. Giovannini I, Boldrini G, Chiarla C, et al: Pathophysiologic correlates of hypocholesterolemia in critically ill surgical patients. Intensive Care Med 1999; 25:748-751
32. Dunham CM, Fealk MH, Sever WE III: Following severe injury, hypocholesterolemia improves with convalescence but persists with organ failure or onset of infection. Crit Care 2003; 7:R145-R153
33. Bonville DA, Parker TS, Levine DM, et al: The relationships of hypocholesterolemia to cytokine concentrations and mortality in critically ill patients with systemic inflammatory response syndrome. Surg Infect (Larchmt) 2004; 5:39-49